- Home
- INKT vs LNZA Comparison
INKT vs LNZA Comparison
Compare INKT & LNZA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INKT | LNZA |
|---|---|---|
| Founded | 2017 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.5M | 61.2M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | INKT | LNZA |
|---|---|---|
| Price | $11.09 | $6.34 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $35.00 | $14.00 |
| AVG Volume (30 Days) | 7.0K | ★ 59.5K |
| Earning Date | 05-15-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 17.00 |
| Revenue | N/A | ★ $55,845,000.00 |
| Revenue This Year | N/A | $55.80 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.36 |
| Revenue Growth | N/A | ★ 12.61 |
| 52 Week Low | $8.48 | $5.02 |
| 52 Week High | $16.80 | $44.00 |
Technical Indicators
Market Signals| Indicator | INKT | LNZA |
|---|---|---|
| Relative Strength Index (RSI) | 47.24 | 51.85 |
| Support Level | $10.76 | $5.38 |
| Resistance Level | $12.20 | $6.50 |
| Average True Range (ATR) | 0.66 | 0.40 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 18.31 | 57.82 |
Price Performance
Historical ComparisonAbout INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
About LNZA LanzaTech Global Inc.
LanzaTech Global Inc is a provider of carbon management and conversion technologies, focused on transforming waste materials into high-value fuels, chemicals, and critical industrial inputs. Its mission is to drive energy resilience, industrial competitiveness, and supply chain security by leveraging scalable biotechnology solutions to maximize the value of domestic resources. The company operates in North America, Europe, the Middle East, Africa (EMEA), Asia, and Australia, with the majority of its revenue generated from North America.